Idorsia seen up after FDA breakthrough designation for pediatric insomnia drug

** Shares in Swiss biopharmaceutical company Idorsia IDIA.S are seen up about 4.2% in premarket trading after the US FDA granted Breakthrough Therapy Designation to daridorexant for pediatric insomnia disorder

** The company said the designation recognizes positive clinical evidence and a significant unmet medical need, with no FDA-approved drug treatments currently available for pediatric insomnia

** Idorsia plans to start a Phase 3 study in pediatric insomnia in the second half of 2027

** Shares were up about 2% year-to-date at Tuesday's close